#ACRBest https://t.co/nx3bzhmeBW

There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/2ExboBvo2W https://t.co/FuqXdFFwqP

What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof

The perks of a conference in San Diego The midday break with a view 🌞 🛥️ @RheumNow #ACR23 https://t.co/IRh7IRpWJz

A#2545 IV SEC for SpA #ACR23 @Rheumow Approved by FDA, though diff dose Who: Medicare/cost/QoL benefit for IV or obese (wt based dose) W16: 41% ASAS40 v 23% PBO W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%) SAE 6%, discontinuation 3.5% #ACRBest https://t.co/ruW0ys49gk

Development of New classification crieteria to target patients earlier in thier #OA disease course! One tatget molecule will not solve this heterogeneous disease! @rheumnow #ACR23 https://t.co/waynA6RdUg

Intriguing data on #GCA treated with tocilizumab #aneurysm still occurs #vasculitis https://t.co/6cPlFRReLJ

• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1
• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1
• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1

A#2546 Anti-IFX Ab in AS #ACR23 @RheumNow Anti-IFX in 45% in f/u, 85% in 1st yr MTX decr anti-IFX (18 v 42%) Anti-IFX - higher inflamm markers, infus rxn, lower serum levels and Rx fail Pt w/o anti-IFX Ab more likely to tolerate tapering https://t.co/eN9SqGyGgm

Nepal et al. No increased risk of GI perforation for tocilizumab in GCA HR 1.05 . Diverticulitis (RR 3.51), IV methylprednisolone (RR 5.41) risk factors. This fits with my priors, steroids are a bigger risk than tocilizumab. Abstr#2560 #ACR23 @RheumNow https://t.co/BAmBQA0kEP https://t.co/zRjmDIkOHp

After attaining #remission or #LLDAS after a flare - HALF flare over f/u esp if tapering pred to <7.5 or 5 mg. #HCQ was protective. 65% got LLDAs and 45% rem in 1/2 yr - longer time to get #remission #2553 #ACR23 @RheumNow @ACRheum #ACRbest Asian cohort of #SLE largest@in world https://t.co/yBBqYJZVOe

Great work @HoromanskiMd on a vasculitis in pregnancy plenary session! #ACR23 https://t.co/WSmqJjfBes

• https://twitter.com/EBRheum/status/1724505301435720055/photo/1

TM65 @ #ACR23 65 yo white M p/w 9mo of cryptogenic strokes. PMH: HTN, Crohn's - 07/2022: CRAO, BMRI: L frontal lobe infarct --> ASA, Atorvastatin started - 09/2022: weakness, vision changes --> BMRI: multifocal subacute infarcts --> Apixaban started, Vedolizumab started for… https://t.co/pjoCv7PH9Y https://t.co/YUN78nn6Xb

Synovial tissue histology correlates w/ several clinical parameters in early naive RA Combination ohigh CD68 infiltrate Fibrinoid Necrosis in tissue asso w/ -better DA reduction -higher EULAR moderate/good resp Included in a prediction model (AUC0.7) @RheumNow #ACR23 ABST2483 https://t.co/2jCMSzV7ak

Fantastic presentation by Desh Nepal from MCW on risk of GI perforation in patients with #GCA Low incidence , no association with TCZ, but increased risk with IV methylprednisolone and h/o diverticulitis. @EBRheum #ACR23 https://t.co/bgvmjAXBEY

Kaymakci et al. 49 GCA patients in clinical remission undergoing thoracic aortic surgery. Active aortitis in 82%. Abstr#2557 #ACR23 @RheumNow https://t.co/WQh47LThGD https://t.co/DeORKmjYP7